[go: up one dir, main page]

SG10201913573UA - Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins - Google Patents

Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Info

Publication number
SG10201913573UA
SG10201913573UA SG10201913573UA SG10201913573UA SG10201913573UA SG 10201913573U A SG10201913573U A SG 10201913573UA SG 10201913573U A SG10201913573U A SG 10201913573UA SG 10201913573U A SG10201913573U A SG 10201913573UA SG 10201913573U A SG10201913573U A SG 10201913573UA
Authority
SG
Singapore
Prior art keywords
type
compositions
methods
chimeric proteins
extracellular domains
Prior art date
Application number
SG10201913573UA
Inventor
Taylor Schreiber
George Fromm
Silva Suresh De
Neal SCHILLING
Original Assignee
Heat Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heat Biologics Inc filed Critical Heat Biologics Inc
Publication of SG10201913573UA publication Critical patent/SG10201913573UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201913573UA 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins SG10201913573UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235727P 2015-10-01 2015-10-01
US201562263313P 2015-12-04 2015-12-04
US201662372574P 2016-08-09 2016-08-09

Publications (1)

Publication Number Publication Date
SG10201913573UA true SG10201913573UA (en) 2020-03-30

Family

ID=58424302

Family Applications (5)

Application Number Title Priority Date Filing Date
SG10201913573UA SG10201913573UA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG11201801984TA SG11201801984TA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913591SA SG10201913591SA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913597VA SG10201913597VA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913576RA SG10201913576RA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Family Applications After (4)

Application Number Title Priority Date Filing Date
SG11201801984TA SG11201801984TA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913591SA SG10201913591SA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913597VA SG10201913597VA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913576RA SG10201913576RA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Country Status (16)

Country Link
US (14) US10183060B2 (en)
EP (2) EP3356393A4 (en)
JP (3) JP6981973B2 (en)
KR (1) KR20180051651A (en)
CN (3) CN108350055B (en)
AU (3) AU2016331076B2 (en)
BR (1) BR112018006578A2 (en)
CA (1) CA2999280A1 (en)
IL (4) IL258029B (en)
MX (2) MX389750B (en)
PH (1) PH12018500694A1 (en)
RU (2) RU2766200C1 (en)
SA (1) SA518391219B1 (en)
SG (5) SG10201913573UA (en)
UA (1) UA126549C2 (en)
WO (1) WO2017059168A1 (en)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
NZ739503A (en) 2015-07-16 2023-06-30 Bioxcel Therapeutics Inc A novel approach for treatment of cancer using immunomodulation
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
CA3047708A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A sirpalpha-41bbl fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
CN110536693B (en) 2017-01-05 2023-12-22 卡尔医学有限公司 PD1-41BBL fusion proteins and methods of using the same
KR20190124247A (en) * 2017-02-27 2019-11-04 샤턱 랩스 인코포레이티드 CSF1R-based chimeric protein
CN118184797A (en) * 2017-02-27 2024-06-14 沙塔克实验室有限公司 VSIG8-based chimeric proteins
MY207687A (en) 2017-02-27 2025-03-12 Shattuck Labs Inc Tigit- and light-based chimeric proteins
CN111372600A (en) * 2017-03-24 2020-07-03 奥菲斯生物科学公司 PantId for treatment of autoimmune disease
KR20180120893A (en) * 2017-04-28 2018-11-07 재단법인 목암생명과학연구소 Fusion protein comprising pvr and 4-1bbl, and use thereof
WO2019023483A1 (en) * 2017-07-26 2019-01-31 Oncorus, Inc. Oncolytic viral vectors and uses thereof
CN109646678A (en) * 2017-10-12 2019-04-19 中国科学院上海生命科学研究院 SUN2 albumen, its pharmaceutical applications and drug
CN108384795A (en) * 2017-10-13 2018-08-10 江苏西迪尔生物技术有限公司 Act on synthetic gene and verification method and the application of TME immune effector cells
CN111278865B (en) * 2017-10-26 2023-04-25 盛禾(中国)生物制药有限公司 Novel recombinant fusion proteins, their preparation and use
KR20200085780A (en) * 2017-11-07 2020-07-15 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 LILRB4 targeting with CAR-T or CAR-NK cells in the treatment of cancer
WO2019136316A1 (en) * 2018-01-04 2019-07-11 Washington University Compositions and methods for inhibition of alphavirus infection
KR102171766B1 (en) * 2018-02-02 2020-10-29 주식회사 뉴라클제네틱스 PD-1 Variants with Enhanced PD-L1 Binding Affinity
CN111971297A (en) * 2018-05-16 2020-11-20 韩国亿诺生物有限公司 Pharmaceutical composition for preventing or treating cancer comprising LRIT2 inhibitor as active ingredient
JP2021524282A (en) * 2018-05-17 2021-09-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Receptor inhibition by phosphatase mobilization
MX2020014031A (en) * 2018-06-21 2021-05-12 Shattuck Labs Inc Heterodimeric proteins and uses thereof.
MX2021000047A (en) * 2018-07-11 2021-05-12 Kahr Medical Ltd Pd1-4-1bbl variant fusion protein and methods of use thereof.
US12134638B2 (en) * 2018-07-11 2024-11-05 Kahr Medical Ltd. SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
JP2022512540A (en) * 2018-08-29 2022-02-07 シャタック ラボ，インコーポレイテッド FLT3L chimeric protein
WO2020047329A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof
CN112839952A (en) * 2018-08-29 2021-05-25 沙塔克实验室有限公司 Combination therapy comprising PD-1-based chimeric protein
WO2020047322A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising tim-3-based chimeric proteins
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
US20210324041A1 (en) * 2018-08-29 2021-10-21 Shattuck Labs, Inc. Combination therapies
CN109053902B (en) * 2018-09-11 2021-06-15 河南科技大学 A kind of chimeric protein AQP4-CH2, preparation and application
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US20220025061A1 (en) * 2018-12-10 2022-01-27 Bioxcel Therapeutics, Inc. Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
WO2020127369A1 (en) * 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
US11098093B2 (en) * 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
PH12021551475A1 (en) * 2019-01-07 2022-05-02 Shattuck Labs Inc Heterodimeric proteins for modulating gamma delta t cells
JP2022524178A (en) * 2019-01-07 2022-04-28 セルリス パルティシパソエス リミターダ How to Modulate Tumor Microenvironment with Bispecificity in Tandem Receptor CAR
WO2020150149A1 (en) * 2019-01-14 2020-07-23 Regents Of The University Of Minnesota Cd200ar ligands for cancer immunotherapy
CN111606999B (en) * 2019-02-26 2022-09-06 南京惟亚德生物医药有限公司 Replicative oncolytic adenovirus with functions of activating immune co-stimulatory signaling pathway and blocking immune checkpoint and application thereof
JP2022522479A (en) * 2019-02-28 2022-04-19 シャタック ラボ，インコーポレイテッド Combination therapy
CN114126663A (en) * 2019-05-16 2022-03-01 沙塔克实验室有限公司 NK cell directed chimeric proteins
EP3986442A4 (en) * 2019-06-21 2023-10-25 Shattuck Labs, Inc. T CELL EXPRESSING CHIMERIC PROTEIN
BR112022000319A2 (en) * 2019-07-11 2022-03-15 Kahr Medical Ltd Heterodimers and methods of using them
JP2022545439A (en) * 2019-08-21 2022-10-27 アスクジーン・ファーマ・インコーポレイテッド NOVEL IL-21 PRODRUGS AND METHODS OF USE THEREOF
WO2021041958A1 (en) * 2019-08-30 2021-03-04 Shattuck Labs. Inc. Chimeric proteins in autoimmunity
CN112480237B (en) * 2019-09-12 2023-10-17 上海津曼特生物科技有限公司 Fusion protein and preparation method and application thereof
CN110592172B (en) * 2019-10-29 2021-05-28 华中农业大学 Methods and targets for screening JEV resistance genes using CRISPR/Cas9 knockout library technology
JP2023503840A (en) * 2019-11-14 2023-02-01 ルートヴィヒ インスティテュート フォー キャンサー リサーチ リミテッド Compositions and methods for immunotherapy
CN110964119A (en) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 Anti-malarial dimeric immunoadhesin, pharmaceutical composition and use
US20210230248A1 (en) * 2020-01-25 2021-07-29 Jun Chen Multivalent pharmacophores for high avidity and overexpressed-target specific binding and uses thereof
CN111826400A (en) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 Preparation method of bispecific antibody NK cell, cell and application thereof
CN111849913B (en) * 2020-07-31 2021-05-25 南京北恒生物科技有限公司 Engineered immune cells and uses thereof
JP2023546725A (en) * 2020-10-26 2023-11-07 シャタック ラボ，インコーポレイテッド Homodimeric and heterodimeric proteins including butyrophilins
EP4237000A4 (en) * 2020-11-02 2024-09-18 Athae Bio, Inc. MULTIMER FUSION PROTEINS WITH TWO DOMAINS
US20240016892A1 (en) * 2020-12-03 2024-01-18 Shattuck Labs, Inc. Methods of treating cancer using tigit-and light-based chimeric proteins
KR102671409B1 (en) * 2021-03-02 2024-05-31 진화섭 Recombinant protein which induces cytotoxicity in CD30 expressing cell and the composition comprising the same for treating cancer
JP2024508540A (en) * 2021-03-05 2024-02-27 シャタック ラボ，インコーポレイテッド Combination therapy using SIRPα-based chimeric proteins
WO2022187583A1 (en) * 2021-03-05 2022-09-09 Shattuck Labs, Inc. Combination therapies with tim-3-based chimeric proteins
KR20220138909A (en) * 2021-04-06 2022-10-14 주식회사 이뮤노로지컬디자이닝랩 Chimeric antigen receptor specifically binding to CD47 and use thereof
US20250092143A1 (en) * 2021-07-23 2025-03-20 University Of Southern California Genetically engineered multifunctional exosomes for immunotherapy
EP4384280A4 (en) * 2021-08-12 2025-10-01 Baylor College Medicine MANIPULATED SOLUBLE DECOY RECEPTORS TO IMPROVE CANCER IMMUNOTHERAPY
WO2023077156A1 (en) * 2021-11-01 2023-05-04 Shattuck Labs, Inc. Modified mrna therapeutics
US20250051410A1 (en) * 2021-12-23 2025-02-13 Kahr Medical Ltd. Lilrb polypeptides and uses thereof
EP4436555A4 (en) * 2022-01-20 2026-01-28 Exocure Sweden Ab MEMBRANE PROTEINS EXPRESSING RECOMBINANT CELL LINE AND VESCLES MADE THEREOF
US20250388646A1 (en) * 2022-07-01 2025-12-25 Fate Therapeutics, Inc. Enhancing effector cell durability and efficacy in adoptive cell therapies
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN121285385A (en) 2023-05-12 2026-01-06 金麦安博股份有限公司 Antibodies capable of binding to OX40, variants thereof and uses thereof
TW202540189A (en) 2023-11-30 2025-10-16 德商生物新技術公司 Antibodies capable of binding to ox40 in combination therapy
CN117886891B (en) * 2024-03-15 2024-06-07 黑龙江八一农垦大学 Polypeptide targeting macrophage CD169 receptor and application thereof
CN120721960B (en) * 2025-08-19 2025-11-21 上海金域医学检验所有限公司 An indicator reagent, kit, and preparation process for detecting autoimmune encephalitis antibodies.

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH07509694A (en) 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン Mutated steroid hormone receptors, their uses and molecular switches for gene therapy
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
AU6827094A (en) * 1993-05-07 1994-12-12 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
ES2219679T3 (en) 1995-10-18 2004-12-01 Akzo Nobel N.V. COMBINATION VACCINE AGAINST NEWCASTLE DISEASE.
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
ATE360031T1 (en) 2000-01-03 2007-05-15 Tr Associates L L C CHIMERIC PROTEINS AND APPLICATIONS
US20110041190A1 (en) 2002-10-31 2011-02-17 Tykocinski Mark L Novel chimeric proteins
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7737260B2 (en) * 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Protein complex using an immunoglobulin fragment and method for the preparation thereof
EP1456652A4 (en) * 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc AGENTS MODULATING IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF
AU2003303082B2 (en) * 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
JP4685764B2 (en) * 2003-04-10 2011-05-18 アボット バイオセラピューティクス コーポレイション Modification of antibody FcRn binding affinity or serum half-life by mutagenesis
KR20060052681A (en) * 2003-05-23 2006-05-19 와이어쓰 Gitr ligand and gitr ligand-related molecules and antibody and uses thereof
EP1685159B1 (en) * 2003-10-03 2012-08-01 Brigham & Women's Hospital Tim-3 polypeptides
EP1750746A1 (en) * 2004-06-04 2007-02-14 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat autoinflammatory disease
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP2006345852A (en) 2005-06-16 2006-12-28 Virxsys Corp Antibody complex
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CA2652570A1 (en) 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
RU2487888C2 (en) 2006-06-12 2013-07-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Single-chain multivalent binding proteins with effector function
EP2038303A2 (en) * 2006-06-21 2009-03-25 Genentech, Inc. Crystal structure of ox40l and ox40l complexed with ox40 receptor
WO2008061377A1 (en) * 2006-11-22 2008-05-29 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
DK3056515T4 (en) 2008-01-15 2025-10-20 Univ Leland Stanford Junior METHOD FOR MANIPULATING PHAGOCYTOSIS MEDIATED BY CD47
US20090226435A1 (en) * 2008-03-08 2009-09-10 Sanjay Khare Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
HUE036780T2 (en) * 2008-04-09 2018-07-30 Genentech Inc New compositions and methods for treating immunologically related diseases
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
US8039437B2 (en) 2008-06-30 2011-10-18 The Trustees Of The University Of Pennsylvania Fn14/TRAIL fusion proteins
AU2009266873A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc TGF-beta antagonist multi-target binding proteins
CN107056951A (en) * 2008-10-02 2017-08-18 阿帕特夫研究和发展有限公司 CD86 antagonist Mutiple Targets associated proteins
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
KR20110112299A (en) * 2008-12-19 2011-10-12 노파르티스 아게 Soluble polypeptide for use in the treatment of autoimmune and inflammatory disorders
CA2755198A1 (en) 2009-03-13 2010-09-16 Mark L. Tykocinski Ox40/trail fusion proteins
CN102939303A (en) * 2009-12-22 2013-02-20 诺瓦提斯公司 Tetravalent cd47-antibody constant region fusion protein for use in therapy
PL2542590T5 (en) 2010-03-05 2020-08-10 The Johns Hopkins University Compositions and Methods for Target Immunomodulatory Antibodies and Fusion Proteins
WO2012042480A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
CN103261217B (en) 2010-11-11 2017-04-26 港大科桥有限公司 Soluble pd-1 variants, fusion constructs, and uses thereof
DK2697257T3 (en) * 2011-04-13 2017-01-30 Bristol Myers Squibb Co FC FUSION PROTEINS INCLUDING UNKNOWN LINKERS OR EVENTS
US10179164B2 (en) 2011-05-25 2019-01-15 Cel-Sci Corporation Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
CN102850458B (en) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 Novel recombined dual-function fusion protein and its preparation method and application
CN103946388A (en) * 2011-06-28 2014-07-23 英伊布里克斯有限责任公司 Wap domain fusion polypeptides and methods of use thereof
ES2888651T3 (en) 2011-07-29 2022-01-05 Univ Pennsylvania costimulatory switching receptors
WO2013119202A1 (en) 2012-02-06 2013-08-15 Providence Health & Services - Oregon Cancer treatment and monitoring methods using ox40 agonists
CA2947354C (en) * 2012-04-30 2024-03-19 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
PT2850106T (en) 2012-05-18 2022-07-18 Aptevo Res & Development Llc Bispecific scfv immunofusion (bif)
EP2858673A4 (en) 2012-06-06 2016-06-22 Oncomed Pharm Inc BINDING AGENTS MODULATING THE HIPPO SIGNALING PATH AND USES THEREOF
CN103566377A (en) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 Targeted immunotherapy for cancer
EP4116331A1 (en) 2012-12-17 2023-01-11 PF Argentum IP Holdings LLC Treatment of cd47+ disease cells with sirp alpha-fc fusions
CN105026424A (en) 2013-01-01 2015-11-04 卡尔医疗有限公司 Stabilized form of signal conversion protein fusion protein, and methods of use and preparation thereof
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
US9873747B2 (en) 2013-01-31 2018-01-23 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson FUSION PROTEINS FOR MODULATING LYMPHOCYTES T REGULATORS AND EFFECTORS
EP2951209A4 (en) 2013-01-31 2016-06-22 Univ Jefferson AGONISTSFUSION PROTEIN FOR CD40-OX40 AND USES THEREOF
US9657082B2 (en) 2013-01-31 2017-05-23 Thomas Jefferson University PD-L1 and PD-L2-based fusion proteins and uses thereof
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
WO2014134165A1 (en) 2013-02-26 2014-09-04 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
ES2704411T3 (en) 2013-03-12 2019-03-18 Biocon Ltd Immunomodulatory fusion proteins and methods of manufacturing them
PT3702373T (en) * 2013-09-13 2022-09-27 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
US9371370B2 (en) * 2013-10-15 2016-06-21 Novo Nordisk Healthcare Ag Coagulation factor VII polypeptides
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
KR20160089532A (en) * 2013-12-17 2016-07-27 제넨테크, 인크. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
BR112016013963A2 (en) * 2013-12-17 2017-10-10 Genentech Inc combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3094650A2 (en) 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Multi-specific polypeptide useful for localized tumor immunomodulation
WO2015112534A2 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
KR102314088B1 (en) * 2014-03-24 2021-10-15 이뮨원코 바이오파마슈티컬즈 (상하이) 컴퍼니 리미티드 Novel recombinant bi-functional fusion proteins, preparation and use thereof
WO2015183902A1 (en) 2014-05-29 2015-12-03 Medimmune, Llc Ox40l fusion proteins and uses thereof
EP3160497A4 (en) 2014-06-27 2018-01-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugates for immunotherapy
CN106535914B (en) 2014-08-08 2021-08-27 Alx 肿瘤生物技术公司 SIRP-alpha variant constructs and uses thereof
EP3482766B1 (en) 2014-08-11 2020-05-20 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
LT3180363T (en) 2014-08-15 2019-11-25 Merck Patent Gmbh Sirp-alpha immunoglobulin fusion proteins
SG11201703605QA (en) 2014-11-17 2017-06-29 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
RU2017129236A (en) * 2015-01-26 2019-03-07 Макродженикс, Инк. MULTIValent MOLECULES CONTAINING DR5-BINDING DOMAINS
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41460A (en) 2015-02-03 2017-12-12 Oncomed Pharm Inc TNFRSF LIAISON AGENTS AND THEIR USES
US10046047B2 (en) 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
US9845345B2 (en) 2015-05-18 2017-12-19 Ab Initio Biotherapeutics, Inc. SIRP polypeptide compositions and methods of use
GEP20217326B (en) 2015-08-07 2021-11-25 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. Therapeutic cd47 antibodies

Also Published As

Publication number Publication date
US20170095531A1 (en) 2017-04-06
US11654180B2 (en) 2023-05-23
UA126549C2 (en) 2022-11-02
RU2022102624A (en) 2022-03-10
HK1258835A1 (en) 2019-11-22
AU2021200367A1 (en) 2021-03-18
IL295423B2 (en) 2023-11-01
US20200261537A1 (en) 2020-08-20
US10493128B2 (en) 2019-12-03
EP3356393A4 (en) 2019-08-07
IL258029A (en) 2018-05-31
US20200246431A1 (en) 2020-08-06
US20190151413A1 (en) 2019-05-23
AU2021200367C1 (en) 2024-05-30
CN108350055A (en) 2018-07-31
IL258029B (en) 2022-09-01
JP2021168699A (en) 2021-10-28
US10653748B2 (en) 2020-05-19
US20180064787A1 (en) 2018-03-08
US20180326008A1 (en) 2018-11-15
RU2766200C1 (en) 2022-02-09
CA2999280A1 (en) 2017-04-06
US20180125935A1 (en) 2018-05-10
US10646545B2 (en) 2020-05-12
EP3356393A1 (en) 2018-08-08
AU2024202253A1 (en) 2024-05-16
MX389750B (en) 2025-03-20
BR112018006578A2 (en) 2018-12-26
MX2018004022A (en) 2018-09-11
IL303586A (en) 2023-08-01
CN116063566A (en) 2023-05-05
US10525102B2 (en) 2020-01-07
US10543253B2 (en) 2020-01-28
US10449233B2 (en) 2019-10-22
US12178847B2 (en) 2024-12-31
SG10201913576RA (en) 2020-02-27
PH12018500694A1 (en) 2018-10-01
SG10201913597VA (en) 2020-02-27
WO2017059168A1 (en) 2017-04-06
IL295423A (en) 2022-10-01
US20250332219A1 (en) 2025-10-30
CN108350055B (en) 2022-11-08
US10660936B2 (en) 2020-05-26
IL303586B2 (en) 2025-03-01
KR20180051651A (en) 2018-05-16
IL295423B1 (en) 2023-07-01
CN116063567A (en) 2023-05-05
IL303586B1 (en) 2024-11-01
JP6981973B2 (en) 2021-12-17
IL316210A (en) 2024-12-01
US10086042B2 (en) 2018-10-02
US20180326004A1 (en) 2018-11-15
AU2016331076A1 (en) 2018-04-05
MX2022001299A (en) 2022-05-10
US11547742B1 (en) 2023-01-10
AU2016331076B2 (en) 2020-12-03
EP4183451A1 (en) 2023-05-24
SG10201913591SA (en) 2020-02-27
EP4183451B1 (en) 2024-11-27
US10183060B2 (en) 2019-01-22
JP2018529363A (en) 2018-10-11
SG11201801984TA (en) 2018-04-27
US10188701B2 (en) 2019-01-29
SA518391219B1 (en) 2022-11-30
US20200101136A1 (en) 2020-04-02
AU2021200367B2 (en) 2024-05-02
US20180326006A1 (en) 2018-11-15
US20180326007A1 (en) 2018-11-15
US20180326005A1 (en) 2018-11-15
JP7303254B2 (en) 2023-07-04
JP2023112132A (en) 2023-08-10

Similar Documents

Publication Publication Date Title
IL258029A (en) Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
HUS2400043I1 (en) Factor viii chimeric proteins and uses thereof
IL256785A (en) Chimeric polypeptide composition and methods for its preparation and use
IL256295A (en) Anti-ntb-a antibodies and related compositions and methods
SG10201914069SA (en) Compositions and methods for tcr reprogramming using fusion proteins
GB201709537D0 (en) Fusion protein comprising three binding domains to 5ta and cd3
ZA201704231B (en) Chimeric protein
PL3240895T3 (en) Compositions and methods for protein glycosylation
SG11201704010UA (en) Fibroin-derived protein composition
IL247632A0 (en) Methods and compositions for secretion of heterologous polypeptides
IL257302B (en) Apoa-1 fusion polypeptides and related compositions and methods
EP3256163A4 (en) Methods and compositions for modulating lilr proteins
GB201506223D0 (en) Chimeric protein
HK1259509A1 (en) Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
HK1260603A1 (en) Chimeric receptors containing traf-inducing domains and related compositions and methods